p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2

Prostate

Volumn 70, Issue 2, 2010, Pages 126-134

  Schneider, Carolin C ^a   Hessenauer, Andrea ^b   Montenarh, Mathias ^a   Götz, Claudia ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Apoptosis; Kinase inhibitor; p53; PARP cleavage; Protein kinase CK2; RNA interference

Indexed keywords

4,5,6,7 TETRABROMOBENZOTRIAZOLE; BENZOTRIAZOLE DERIVATIVE; CASEIN KINASE II; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; UPREGULATION;

APOPTOSIS; CASEIN KINASE II; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; MALE; PROSTATIC NEOPLASMS; TRIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73449102163     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21044     Document Type: Article

References (60)

1. Eder IE, Culig Z, Putz T, Nessler-Menardi C, Bartsch G, Klocker H. Molecular biology of the androgen receptor: From molecular understanding to the clinic. Eur Urol 2001;40:241-251.
2. Bibby AC, Litchfield DW. The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2beta. Int J Biol Sci 2005;1:67-79.
3. Litchfield DW. Protein kinase CK2: Structure, regulation and role in cellular decisions of life and death. Biochem J 2003;369:1-15.
4. Ahmed K, Gerber DA, Cochet C. Joining the cell survival squad: An emerging role for protein kinase CK2. Trends Cell Biol 2002;12:226-230.
5. Ahmed K, Davis AT, Wang HM, Faust RA, Yu SH, Tawfic S. Significance of protein kinase CK2 nuclear signaling in neoplasia. J Cell Biochem 2000:130-135.
6. Faust RA, Gapany M, Tristani P, Davis A, Adams GL, Ahmed K. Elevated protein kinase CK2 activity in chromatin of head and neck tumors: Association with malignant transformation. Cancer Lett 1996;101:31-35.
7. Prowald K, Fischer H, Issinger OG. Enhanced casein kinase II activity in human tumour cell cultures. FEBS Lett 1984;176:479-483.
8. Yenice S, Davis AT, Goueli SA, Akdas A, Limas C, Ahmed K. Nuclear casein kinase 2 (CK-2) acitivity in human normal, benign hyperplastic, and cancerous prostate. Prostate 1994;24: 11-16.
9. Ahmad KA, Wang G, Unger G, Slaton J, Ahmed K. Protein kinase CK2-A key suppressor of apoptosis. Adv Enzyme Regul 2008; 48:179-187.
10. Duncan JS, Litchfield DW. Too much of a good thing: The role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 2008;1784: 33-47.
11. Perea SE, Reyes O, Puchades Y, Mendoza O, Vispo NS, Torrens I, Santos A, Silva R, Acevedo B, Lopez E, Falcon V, Alonso DF. Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer Res 2004;64:7127-7129.
12. Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, Lopez-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, Lopez E, Falcon V, Hernandez I, Solares M, Santana A, Diaz A, Ramos T, Lopez C, Ariosa J, Gonzalez LJ, Garay H, Gomez D, Gomez R, Alonso DF, Sigman H, Herrera L, Acevedo B. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo. Mol Cell Biochem 2008;316:163-167.
13. Lowe SW, Bodis S, Bardeesy N, McClatchey A, Remington L, Ruley HE, Fisher DE, Jacks T, Pelletier J, Housman DE. Apoptosis and the prognostic significance of p53 mutation. Cold Spring Harbor Symp Quant Biol 1994;59:419-426.
14. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008;7:979-987.
15. Pagano MA, Bain J, Kazimierczuk Z, Sarno S, Ruzzene M, Di Maira G, Elliott M, Orzeszko A, Cozza G, Meggio F, Pinna LA. The selectivity of inhibitors of protein kinase CK2. An update. Biochem J 2008;415:353-365.
16. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T 4. Nature 1970;227: 680-682.
17. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-225.
18. Yamane K, Kinsella TJ. CK2 inhibits apoptosis and changes its cellular localization following ionizing radiation. Cancer Res 2005;65:4362-4367.
19. Ahmad KA, Wang G, Ahmed K. Intracellular hydrogen peroxide production is an upstream event in apoptosis induced by down-regulation of casein kinase 2 in prostate cancer cells. Mol Cancer Res 2006;4:331-338.
20. Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K. Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Cell Growth Differ 2004;2:712-721.
21. Wang HM, Davis A, Yu SH, Ahmed K. Response of cancer cells to molecular interruption of the CK2 signal. Mol Cell Biochem 2001;227:167-174.
22. Hamacher R, Saur D, Fritsch R, Reichert M, Schmid RM, Schneider G. Casein kinase II inhibition induces apoptosis in pancreatic cancer cells. Oncol Rep 2007;18:695-701.
23. Di Maira G, Brustolon F, Bertacchini J, Tosoni K, Marmiroli S, Pinna LA, Ruzzene M. Pharmacological inhibition of protein kinaseCK2reverts the multidrug resistance phenotype of aCEM cell line characterized by high CK2 level. Oncogene 2007; 26:6915-6926.
24. Duncan JS, Gyenis L, Lenehan J, Bretner M, Graves LM, Haystead TA, Litchfield DW. An unbiased evaluation of CK2 inhibitors by chemoproteomics: Characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Mol Cell Proteomics 2008;7:1077-1088.
25. Pagano MA, Poletto G, Di Maira G, Cozza G, Ruzzene M, Sarno S, Bain J, Elliott M, Moro S, Zagotto G, Meggio F, Pinna LA. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem 2007;8:129-139.
26. Llobet D, Eritja N, Encinas M, Llecha N, Yeramian A, Pallares J, Sorolla A, Gonzalez-Tallada FJ, Matias-Guiu X, Dolcet X. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene 2007;27:2519-2524.
27. Kim HR, Kim K, Lee KH, Kim SJ, Kim J. Inhibition of casein kinase 2 enhances the death ligand- and natural killer cell-induced hepatocellular carcinoma cell death. Clin Exp Immunol 2008;152:336-344.
28. Di Maira G, Brustolon F, Tosoni K, Belli S, Kramer SD, Pinna LA, Ruzzene M. Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis. Mol Cell Biochem 2008;316:155-161.
29. Wang G, Ahmad KA, Ahmed K. Modulation of death receptor-mediated apoptosis by CK2. Mol Cell Biochem2005;274:201-205.
30. Wang G, Ahmad KA, Ahmed K. Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells. Cancer Res 2006;66:2242-2249.
31. Ravi R, Bedi A. Sensitization of tumor cells to Apo2 ligand/ TRAIL-induced apoptosis by inhibition of casein kinase II. Cancer Res 2002;62:4180-4185.
32. Izeradjene K, Douglas L, Delaney A, Houghton JA. Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene 2005;24:2050-2058.
33. Shen J, Channavajhala P, Seldin DC, Sonenshein GE. Phosphorylation by the protein kinase CK2 promotes calpain-mediated degradation of IkappaBa. J Immunol 2001;167:4919-4925.
34. Le PC, Koumakpayi IH, Lessard L, Saad F, Mes-Masson AM. Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells. Prostate 2005;65:306-315.
35. Song DH, Dominguez I, Mizuno J, Kaut M, Mohr SC, Seldin DC. CK2 phosphorylation of the armadillo repeat region of b-catenin potentiates Wnt signaling. J Biol Chem 2003;278:24018-24025.
36. Wang S, Jones KA. CK2 controls the recruitment of Wnt regulators to target genes in vivo. Curr Biol 2006;16:2239-2244.
37. Krippner-Heidenreich A, Talanian RV, Sekul R, Kraft R, Thole H, Ottleben H, Luscher B. Targeting of the transcription factor Max during apoptosis: Phosphorylation-regulated cleavage by caspase-5 at an unusual glutamic acid residue in position P1. Biochem J 2001;358:705-715.
38. Ruzzene M, Penzo D, Pinna LA. Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 2002;364: 41-47.
39. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 2001;276:993-998.
40. Walter J, Grunberg J, Schindzielorz A, Haass C. Proteolytic fragments of the Alzheimer's disease associated presenilins-1 and -2 are phosphorylated in vivo by distinct cellular mechanisms. Biochemistry 1998;37:5961-5967.
41. Desagher S, Osen-Sand A, Montessuit S, Magnenat E, Vilbois F, Hochmann A, Journot L, Antonsson B, Martinou JC. Phosphorylation of Bid by casein kinases I and II regulates its cleavage by caspase 8. Mol Cell 2001;8:601-611.
42. Li PF, Li JC, Müller EC, Otto A, Dietz R, Von Harsdorf R. Phosphorylation by protein kinase CK2: A signaling switch for the caspase-inhibiting protein ARC. Mol Cell 2002;10:247-258.
43. Tapia JC, Torres VA, Rodriguez DA, Leyton L, Quest AF. Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci USA 2006;103: 15079-15084.
44. Wang G, Ahmad KA, Harris NH, Ahmed K. Impact of protein kinase CK2 on inhibitor of apoptosis proteins in prostate cancer cells. Mol Cell Biochem 2008;316:91-97.
45. Kyprianou N, Bruckheimer EM, Guo Y. Cell proliferation and apoptosis in prostate cancer: Significance in disease progression and therapy. Histol Histopathol 2000;15:1211-1223.
46. Ferrer FA, Rodriguez R. Prostate cancer gene therapy. Hematol Oncol Clin North Am 2001;15:497-508.
47. Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K. Protein kinase CK2 signaling in neoplasia. Histol Histopathol 2001;16: 573-582.
48. Faust RA, Tawfic S, Davis AT, Bubash LA, Ahmed K. Antisense oligonucleotides against protein kinase CK2-alpha inhibit growth of squamous cell carcinoma of the head and neck in vitro. Head Neck 2000;22:341-346.
49. Laramas M, Pasquier D, Filhol O, Ringeisen F, Descotes JL, Cochet C. Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer 2007;43:928-934.
50. Sarno S, Pinna LA. Protein kinase CK2 as a druggable target. Mol Biosyst 2008;4:889-894.
51. Sarno S, Ruzzene M, Frascella P, Pagano MA, Meggio F, Zambon A, Mazzorana M, Di Maira G, Lucchini V, Pinna LA. Development and exploitation of CK2 inhibitors. Mol Cell Biochem 2005; 274:69-76.
52. Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella-Deana A, Shugar D, Pinna LA. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett 2001;496:44-48.
53. Schneider CC, Hessenauer A, Götz C, Montenarh M. DMAT:an inhibitor of protein kinase CK2 induces reactive oxygen species and DNA double strand breaks. Oncol Rep 2009;21:1593-1597.
54. Pagano MA, Andrzejewska M, Ruzzene M, Sarno S, Cesaro L, Bain J, Elliott M, Meggio F, Kazimierczuk Z, Pinna LA. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem 2004;47:6239-6247.
55. Wang G, Unger G, Ahmad KA, Slaton JW, Ahmed K. Down-regulation of CK2 induces apoptosis in cancer cells-a potential approach to cancer therapy. Mol Cell Biochem 2005;274:77-84.
56. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
57. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-412.
58. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002;108:153-164.
59. Meulmeester E, Jochemsen AG. p53: A guide to apoptosis. Curr Cancer Drug Targets 2008;8:87-97.
60. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis 2004;9:691-704.